reexisting diabetes complicates 0.9% of pregnancies in the United States and increases the risk of adverse maternal and neonatal outcomes. [1] [2][3] Specific risks of uncontrolled diabetes in pregnancy include preeclampsia, congenital defects, preterm delivery, macrosomia, and stillbirth (Box).
Comprehensive diabetes care in pregnancy can be considered in the preconception, pregnancy, and postpartum stages.
Methods
We searched the PubMed database from January 1, 2000, to January 31, 2019, for English-language studies related to the management of preexisting diabetes in pregnancy. There are few randomized clinical trials of pregnant vs nonpregnant women, so, although such studies were included, the search was not limited to these studies. Guidelines of major professional societies, metaanalyses, and observational studies were also reviewed. Selected articles were mutually agreed upon by the authors.
Preconception Preconception Counseling and Glycemic Targets
While rates of unintended pregnancy have decreased in recent years, nearly half of pregnancies in the United States are still unplanned. 19 Appropriate prepregnancy planning is one of the most important steps in reducing the risk of birth defects for women with preexisting diabetes because organogenesis occurs very early in pregnancy. The American Diabetes Association (ADA) recommends hemoglobin A 1c (HbA 1c ) of less than 6.5% at conception, with a lower goal of less than 6% during pregnancy if it can be achieved without significant hypoglycemia. 20 Targets may be relaxed to less than 7% if hypoglycemia occurs at lower HbA 1c levels. 20 Discussions regarding the risks of congenital anomalies with unplanned pregnancy and the importance of effective contraception should be initiated at the onset of diabetes or puberty and continued thereafter. Long-acting reversible forms of contraception (LARC), such as implantable progestin or intrauterine devices, should be recommended as first-line therapy for women who do not desire fertility in the near future because these are the most effective forms of contraception. 21, 22 Patients should alert their clinicians before ceasing contraception and, ideally, this step would be preceded by monthly meetings between the patient and care team to optimize glycemic control. Women with diabetes should ideally be referred to a maternalfetal medicine specialist (high-risk obstetrician) prior to conception. These specialists can counsel women on possible maternal and fetal complications and the need for intensified fetal surveillance during pregnancy.
Weight and Nutrition
Obesity is common in individuals with type 2 diabetes, with increasing prevalence in individuals with type 1 diabetes, 23 and represents an independent risk factor for congenital malformations, particularly cardiac defects. 24, 25 Efforts should be made to optimize weight in addition to glycemic control prior to conception. In a 2019 study by Persson et al, 25 the rate of aortic arch defects, atrial septal defect, and patent ductus arteriosus increased incrementally with maternal body mass index (BMI), and the rate of transposition of the great arteries was nearly double (adjusted prevalence rate ratio, All women with diabetes should be referred to a dietician prior to or early in pregnancy. Referral to a registered dietitian is particularly recommended for all women with overweight or obesity to generate a nutrition plan that accounts for pregestational weight and targets at least 5% to 10% loss of body weight prior to conception.
To prevent neural tube defects, prospective mothers should take at least 400 μg of folic acid daily for at least 1 month prior to conception. 35 They should also take 1000 mg of elemental calcium and 600 IU of vitamin D daily while pregnant to support bone health in the neonate 36, 37 ; these nutrients can be prescribed in the form of a prenatal multivitamin and/or consumed via diet.
Diabetes Complications
Prior to pregnancy, women should be screened for complications of diabetes, including retinopathy and nephropathy. Diabetic retinopathy can worsen during pregnancy and with brisk improvement in glycemic control. Worsening of retinopathy with rapidly improved glycemic control is not well understood, although this phenomenon has been observed in nonpregnant populations and is often transient. 38 While pregnancy-induced retinopathy (or worsening of preexisting disease) is unlikely to be permanent, retinopathy progression can threaten vision during pregnancy. All women with type 1 and type 2 diabetes should undergo retinal examination prior to conception, ideally, (particularly women with preexisting diabetic retinopathy) or within the first trimester. Additional ophthalmologic monitoring during and after pregnancy will be guided by extent of the disease.
20
In terms of nephropathy, a urine albumin:creatinine ratio can be obtained for women with diabetes prior to pregnancy, although the standard measurement during pregnancy is a urine protein:creatinine ratio from a 24-hour urine collection. Women with nephropathy should be monitored by a multidisciplinary team that includes a maternal-fetal medicine physician and a nephrologist before and during pregnancy. 45 Guidelines from the United Kingdom recognize end-organ damage as reason to consider lower BP goals (eg, diastolic BP <90 mm Hg). 46 The CHIPS study did not include any women with preexisting diabetes or proteinuria and only 6% of study participants had gestational diabetes, thus, these data are not generalizable to women with preexisting type 1 or type 2 diabetes. 42 However, it is reasonable to consider women with preexisting diabetes at particularly high risk of poor outcomes related to hypertension because they are more likely to have baseline nephropathy. While this concern has yet to be reflected in ADA guidelines, it is sensible for clinicians to consider lower BP targets for pregnant women with diabetic nephropathy. When treating women with hypertension, potentially teratogenic medications, such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, should be discontinued during pregnancy and alternative medications that are considered safe in pregnancy, such as labetalol, nifedipine, or clonidine, should be used to manage blood pressure. 47, 48 Studies have suggested that nondihydropyridine calcium channel blockers, such as diltiazem, decrease proteinuria and thus diltiazem could be considered for women with hypertension and proteinuria during pregnancy, 49 although there are limited studies of this agent in pregnancy.
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Diabetes in pregnancy increases the risk of preeclampsia, so initiation of low-dose aspirin (60 mg to 150 mg daily; usual dose, 81 mg) is recommended between 12 and 28 (ideally before 16) weeks' gestation to reduce this risk. 20 Controversy exists regarding optimal dosing; several meta-analyses have found the reduction in preeclampsia to be greatest in women taking at least 100 mg of aspirin per day. 52,53 While coronary artery disease (CAD) is uncommon in pregnancy, it is associated with high maternal mortality.
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Therefore, clinicians should consider CAD risk factors (ie, advanced maternal age, chronic renal disease, hypertension, smoking, family history of premature CAD) and screen high-risk mothers with an electrocardiogram and/or exercise echocardiogram. Statins should be discontinued when planning pregnancy, although data suggest they are likely not teratogenic.
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For women with type 1 diabetes who are planning for pregnancy, thyroid-stimulating hormone levels should be checked to screen for autoimmune thyroid disease. 20, 54 During Pregnancy
Glucose Monitoring
Intensification of glucose monitoring can be a challenge for women who are pregnant. Women receiving multiple daily injections (MDI) of insulin are advised to monitor capillary glucose in the fasting, preprandial, and (1-or 2-hour) postprandial states and to undergo at least 7 glucose checks daily. Recommended targets are less than 95 mg/dL for fasting glucose, less than 140 mg/dL for 1-hour postprandial glucose, and less than 120 mg/dL for 2-hour postprandial glucose ( Table 1) . 20 Close glucose monitoring is essential to (1) Although DKA occurs at a higher frequency in women with type 1 diabetes, all pregnant women with diabetes are predisposed to DKA because pregnancy promotes insulin resistance, accelerated lipolysis, and surplus of free fatty acids that can be shunted to ketone body production. 62 High levels of human chorionic gonadotropin can lead to nausea and vomiting and thereby predispose women to DKA early in pregnancy. In contrast, insulin resistance and metabolic demands increase significantly by the third trimester, which can precipitate DKA via hyperglycemia and relative starvation. 62 Additionally, a major reason for earlier acidosis in pregnancy is lower acid buffering capacity; women who are pregnant have respiratory alkalosis with compensatory metabolic acidosis and, thus, lower bicarbonate levels. 63 Pregnant women can develop DKA with normal glucose values, which may be partially attributed to glomerular hyperfiltration resulting in glucosuria, 64 so euglycemia should not provide false reassurance to patients and clinicians. 65 Women who are pregnant or planning pregnancy should be educated regarding ketone testing and supplied with urine or serum ketone testing supplies. Women (particularly with type 1 diabetes) should measure urine ketones after episodes of vomiting or inability tolerate food or drink, when otherwise ill, or if glucose remains greater than 250 mg/dL after appropriate measures. Women with ketonuria should seek medical attention for prompt treatment to reduce maternal and neonatal risk.
Nutrition and Weight During Pregnancy
Even in nonobese women, weight gain exceeding recommended targets during pregnancy can be associated with worse perinatal outcomes, including macrosomia, shoulder dystocia, and neonatal hypoglycemia. 66 Thus, pregnancy requires close attention to food intake to ensure strict glycemic control and avoid excess weight gain. However, care should be taken to avoid inadequate carbohydrate intake, which can lead to starvation and ketosis in pregnancy. To minimize the risk of DKA, women are advised to consume adequate carbohydrates 62 ; a daily minimum of 175 g of carbohydrates is recommended for pregnant women by the Dietary Reference Intakes, 20 although nutrition plans should be individualized.
Approach to Insulin Management
Women with preexisting diabetes commonly require basal-bolus regimens to achieve glycemic targets. Specifically, women with type 2 diabetes who are treated with diet alone, oral agents, or basal insulin will need education regarding intensive insulin management that may be necessary to achieve preconception targets or that will need to be implemented during pregnancy. Insulin remains the cornerstone of therapy for pregnant women with diabetes because of glucose-lowering potency as well as demonstrated safety during pregnancy because insulin does not cross the placenta. Women are frequently switched to basal insulins detemir or neutral protamine Hagedorn during pregnancy because these have been more extensively studied than newer, basal insulin analogues. Short-acting/rapid-acting insulins regular, lispro, and aspart have also been well studied. There are reports of safe and successful pregnancies in women taking insulin glargine during pregnancy. 67 Because insulins glargine and degludec are unlikely to cross the placenta, 68 there is no compelling evidence to suggest that women should be switched off of these insulins when pregnant, particularly when they are already achieving excellent glycemic control. MDI and insulin pump therapy, also called continuous subcutaneous insulin infusion (CSII), are both effective approaches in pregnancy. While insulin pumps offer obvious advantages in terms of flexibility of bolusing, there is insufficient evidence to recommend one method over the other. 69 However, if CSII is to be initiated, it should be started well before conception to allow women time to acclimate to the pump and ensure glycemic control before pregnancy. Also, women using CSII require a subcutaneous insulin plan in case of pump malfunction. A prespecified analysis of the CONCEPTT trial was to compare glycemic control and pregnancy outcomes in women with type 1 diabetes who were using MDI vs CSII at study inclusion.
Researchers observed better glycemic outcomes, less gestational hypertension and neonatal hypoglycemia, and fewer neonatal intensive care unit admissions with MDI vs CSII, although women were not randomized to method of insulin delivery in this trial. 70 Closed-loop insulin delivery systems that integrate CGM data with CSII may hold promise in the management of diabetes in pregnancy but, currently, glucose targets are not customizable and are typically too high for pregnancy. For instance, the MiniMed 670G (Medtronic) insulin pump has an "auto-mode" commercial hybrid closed-loop system that utilizes an algorithm to target an average glucose of 120 mg/dL, 71 
Noninsulin Medications
Oral agents are not recommended as first-line therapy for pregnant women with diabetes because they are typically not capable of overcoming the insulin resistance of pregnancy in women with type 2 diabetes and are not effective in individuals with type 1 diabetes. Furthermore, metformin and sulfonylureas cross the placenta whereas insulin does not. There remains significant controversy about the use of metformin among pregnant women. Per the ADA guidelines, women with type 2 diabetes who are prescribed metformin prior to pregnancy should be switched to insulin when they become pregnant. 20 However, many women with polycystic ovary syndrome and/or obesity continue receiving metformin through the first trimester, and not all professional organizations agree on the use of metformin during pregnancy. 77 Studies have shown an association of metformin treatment with less maternal weight gain, primarily in women with gestational diabetes 20,78 as well as women with type 2 diabetes. 79 However, 2 studies that examined children of women who were treated with metformin during pregnancy suggest that metformin may have long-term effects on offspring. 78,80 At 9 years of age, children of women with gestational diabetes who were exposed to metformin in utero had larger measures of subcutaneous fat compared with children exposed to insulin. 78 At 4 years of age, children of women with polycystic ovarian syndrome who were exposed to metformin had higher BMI and increased prevalence of obesity (32%) compared with children exposed to a placebo (18%). 80 Thus, it is possible that metformin has long-term effects on fetal and childhood development, perhaps due to its effects on mitochondrial respiration, growth inhibition, or cell metabolism and proliferation. 77 A randomized clinical trial is currently under way (the MiTy Trial; NCT01353391) 81 to investigate perinatal and neonatal outcomes in pregnant women prescribed metformin vs placebo as an adjunct to insulin to manage type 2 diabetes. Additional studies will still be needed to determine long-term effects of metformin on offspring.
For women who decline insulin, metformin can be continued, although the safety data and high likelihood of treatment failure necessitating insulin should be fully discussed with the patient.
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Sulfonylureas are not recommended for pregnant women with preexisting diabetes. In a 2018 study by Sénat and colleagues, 82 glyburide was compared with insulin in pregnant women with gestational diabetes and there was a failure to demonstrate noninferiority of glyburide for the composite outcome of macrosomia, neonatal hypoglycemia, and hyperbilirubinemia (outcome occurred in 23.4% of neonates born to women treated with insulin vs 27.6% of neonates born to women treated with glyburide). 82 Sulfonylureas lack data to support their use in pregnancy and, in contrast to metformin, they tend to promote weight gain rather than weight stability. 83 Thiazolidinediones also contribute to weight gain and lack safety data regarding pregnancy. Newer glucose-lowering agents, including dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium glucose-cotransporter 2 inhibitors, are also not recommended in pregnancy because of a lack of safety data. Women who are prescribed these agents should be using effective contraception and counseled on cessation of these medications ideally 3 months prior to conception. Interestingly, the GLP-1 receptor agonist exenatide appears to cross the placenta in only negligible amounts. 84 Because fetal exposure to GLP-1 receptor agonists is likely to be low, clinicians should be cautious of abruptly stopping these agents without concurrent initiation of other therapy, such as insulin, because the risk of uncontrolled hyperglycemia may exceed fetal risk of the drug.
Fetal Monitoring and Delivery Planning
Women with diabetes who become pregnant require increased fetal monitoring (Table 3) . Women should have a detailed anatomy scan at 18 to 20 weeks' gestation and fetal echocardiography can be considered (particularly if HbA 1c is >6.5%). 21 Ultrasonography is commonly used to assess fetal growth in the third trimester, though a specific approach to timing and frequency has not been demonstrated as superior. Most clinicians obtain formal fetal monitoring, such as the nonstress test, the biophysical profile, or the modified biophysical profile, starting at 32 weeks' gestation (often once or twice weekly). The American College of Obstetricians and Gynecologists recommends delivery at 39 0/7 to 39 6/7 weeks' gestation in women without vascular complications and with wellcontrolled blood glucose values, but recommends earlier delivery at 36 0/7 to 38 6/7 weeks' gestation for women who have vascular complications or poor glycemic control.
Postpartum
During delivery, most cases of diabetes are managed with intravenous insulin, although this is dependent on local institutional policies. Women become exquisitely sensitive to insulin with delivery of the placenta. Insulin requirements may decrease to as low as 50% of prepregnancy needs, particularly in patients with type 1 diabetes (Table 2) . Therefore, it is prudent to administer 50% to 90% of prepregnancy insulin doses, and this decision can be guided by immediate postpartum glucose values, intravenous insulin needs, and food intake. It is helpful for outpatient clinicians to document prepregnancy insulin doses leading up to delivery.
Breastfeeding
Benefits of breastfeeding include loss of excess weight in mothers, infant bonding, and lower future risk of obesity and type 2 diabetes in offspring. 85, 86 Women who breastfeed are predisposed to hypoglycemia because carbohydrates are expelled into breast milk, so insulin doses may need to be lowered during this time and/or women can be counseled to consume a snack with lactation to avoid hypoglycemia. An increase of 500 kcal per day from prepregnancy caloric intake is generally recommended for nonobese women who are breastfeeding.
21,87

Contraception
Most women do not plan on conceiving within 1 year of giving birth, 88 but fertility may return as soon as 6 weeks after delivery in women who are not exclusively breastfeeding. Thus, the immediate postpartum period represents an opportunity to initiate LARC before women return home and develop barriers to accessing effective contraception. 88 LARC is safe in the postpartum period and early initiation of progestogen does not appear to negatively affect glycemic control, breastfeeding, or infant growth. 88 For women who do not plan to have children in the future or who have end-organ complications resulting in high-risk future pregnancies, tubal ligation can be considered as a permanent form of contraception.
Conclusions
Preexisting diabetes in pregnancy is complex and is associated with significant maternal and neonatal risk. Optimization of glycemic control, medication regimens, and careful attention to comorbid conditions by a multidisciplinary team that includes maternal-fetal medicine physicians, endocrinologists, ophthalmologists, and nutritionists can help mitigate these risks and ensure quality diabetes care before, during, and after pregnancy.
